RESUMO
Purpose: The objectives were to investigate the effect of transscleral iontophoresis of macromolecules in vitro and in vivo, to study the importance of electroosmosis on macromolecules of low charge to mass ratio, and to evaluate transscleral iontophoresis efficacy in a choroidal neovascularization (CNV) animal model. Methods: Through in vitro transport experiments, the permeability coefficients of macromolecules [eg, immunoglobulin G (IgG), dextran 70 kDa] were determined under different conditions. The effect of ionic strength formulations and iontophoretic conditions was studied on the distribution of IgG and bevacizumab into the eye in vivo. Magnetic resonance imaging (MRI) was utilized to evaluate in vivo real time distribution of gadolinium-labeled albumin (Galbumin) following iontophoresis. The efficacy between no treatment, intravitreal injection (IVT), and iontophoresis of bevacizumab on a CNV model of subretinal injection of adeno-associated virus encoding human VEGF-165 was investigated. Results: The permeability data suggested a significant effect of ionic strength on the iontophoretic transport of macromolecules. Transscleral iontophoresis of IgG at 4 mA with a low ionic strength formulation was about 600 times greater than passive diffusion and 14-fold over a conventional formulation in vitro. Approximately 0.6 mg of bevacizumab can be delivered into the rabbit eye in vivo with a 20-min treatment of iontophoresis. MRI showed that Galbumin was in the posterior tissues after iontophoresis. In the CNV model, the iontophoresis and IVT methods of bevacizumab delayed retinal neovascularization by 4 and 8 weeks, respectively. Conclusions: Transscleral iontophoresis is capable of delivering macromolecule drugs through the conjunctiva and sclera, eventually exposing the retina/choroid to the drugs.
Assuntos
Bevacizumab/farmacocinética , Neovascularização de Coroide/tratamento farmacológico , Sistemas de Liberação de Medicamentos/métodos , Iontoforese/métodos , Substâncias Macromoleculares/farmacocinética , Inibidores da Angiogênese/administração & dosagem , Inibidores da Angiogênese/farmacocinética , Inibidores da Angiogênese/uso terapêutico , Animais , Bevacizumab/administração & dosagem , Bevacizumab/uso terapêutico , Transporte Biológico , Túnica Conjuntiva/efeitos dos fármacos , Túnica Conjuntiva/metabolismo , Eletro-Osmose/métodos , Imunoglobulina G/efeitos dos fármacos , Imunoglobulina G/metabolismo , Injeções Intravítreas , Substâncias Macromoleculares/administração & dosagem , Imageamento por Ressonância Magnética/métodos , Modelos Animais , Permeabilidade/efeitos dos fármacos , Coelhos , Esclera/efeitos dos fármacos , Esclera/metabolismoRESUMO
Bladder cancer (BC) is a prevalent disease with high morbidity and mortality; however, inâ vivo optical imaging of BC remains challenging because of the lack of cancer-specific optical agents with high renal clearance. Herein, a macromolecular reporter (CyP1) was synthesized for real-time near-infrared fluorescence (NIRF) imaging and urinalysis of BC in living mice. Because of the high renal clearance (ca. 94 % of the injection dosage at 24â h post-injection) and its cancer biomarker (APN=aminopeptidaseâ N) specificity, CyP1 can be efficiently transported to the bladder and specially turn on its NIRF signal to report the detection of BC in living mice. Moreover, CyP1 can be used for optical urinalysis, permitting the exâ vivo tracking of tumor progression for therapeutic evaluation and easy translation of CyP2 as an inâ vitro diagnostic assay. This study not only provides new opportunities for non-invasive diagnosis of BC, but also reveals useful guidelines for the development of molecular reporters for the detection of bladder diseases.
Assuntos
Aminopeptidases/metabolismo , Biomarcadores Tumorais/metabolismo , Corantes Fluorescentes/farmacocinética , Substâncias Macromoleculares/farmacocinética , Neoplasias da Bexiga Urinária/diagnóstico por imagem , 2-Hidroxipropil-beta-Ciclodextrina/química , 2-Hidroxipropil-beta-Ciclodextrina/metabolismo , Animais , Transporte Biológico , Carbocianinas/química , Humanos , Substâncias Macromoleculares/administração & dosagem , Substâncias Macromoleculares/urina , Camundongos , Neoplasias Experimentais , Imagem Óptica , Espectroscopia de Luz Próxima ao InfravermelhoRESUMO
Macromolecular drugs, such as proteins and peptides, are lately readily available and used in the treatment of diseases including diabetes and cancer, as well as in therapies such as gene therapy, wound dressing, and tissue engineering. However, the bioavailability, the extent and the rate at which these drugs reach the target tissue are highly dependent on the carrier and on the route of administration. Among the multitude of biocompatible polymers used to design vehicles for macromolecular drugs, polysaccharides are preferred due to their mucoadhesive, antimicrobial, and anti-inflammatory properties. This review aims to give an overview on the evolution of polysaccharide-based vehicles recommended in the controlled delivery of proteins and peptides, mainly reported in the last five years. Both physically and chemically cross-linked drug delivery systems are presented such as: porous hydrogels, polyelectrolyte complexes and layer-by-layer thin films. Even if the pharmaceutical formulations for oral administration of proteins and peptides are preferred, other friendly routes are discussed in this review, such as transdermal delivery.
Assuntos
Sistemas de Liberação de Medicamentos/métodos , Hidrogéis , Peptídeos/farmacocinética , Polímeros , Polissacarídeos , Proteínas/farmacocinética , Animais , Materiais Biocompatíveis/síntese química , Materiais Biocompatíveis/uso terapêutico , Disponibilidade Biológica , Diabetes Mellitus/tratamento farmacológico , Humanos , Hidrogéis/química , Hidrogéis/uso terapêutico , Substâncias Macromoleculares/farmacocinética , Neoplasias/tratamento farmacológico , Polímeros/química , Polímeros/uso terapêutico , Polissacarídeos/química , Polissacarídeos/uso terapêutico , Engenharia TecidualRESUMO
PURPOSE: Optimal efficacy of a macromolecular prodrug requires balancing the rate of drug release with the rate of prodrug elimination. Since circulating macromolecules have different elimination rates in different species, a prodrug optimal for one species will likely not be for another. The objectives of this work were (a) to develop an approach to optimize pharmacokinetics of a PEG~SN-38 prodrug in a particular species, (b) to use the approach to predict the pharmacokinetics of various prodrugs of SN-38 in the mouse and human, and (c) to develop a PEG~SN-38 conjugate that is optimized for mouse tumor models. METHODS: We developed models that describe the pharmacokinetics of a drug released from a prodrug by the relationship between the rates of drug release and elimination of the prodrug. We tested the model by varying the release rate of SN-38 from PEG~SN-38 conjugates in the setting of a constant prodrug elimination rate in the mouse. Finally, we tested the antitumor efficacy of a PEG~SN-38 optimized for the mouse. RESULTS: Optimization of a PEG~SN-38 prodrug was achieved by adjusting the rate of SN-38 release such that the ratio of t1/2,ß of released SN-38 to the t1/2 of prodrug elimination was 0.2-0.8. Using this approach, we could rationalize the efficacy of previous PEGylated SN-38 prodrugs in the mouse and human. Finally, a mouse-optimized PEG~SN-38 showed remarkable antitumor activity in BRCA1-deficient MX-1 xenografts; a single dose gave tumor regression, suppression, and shrinkage of massive tumors. CONCLUSIONS: The efficacy of a macromolecular prodrug can be optimized for a given species by balancing the rate of drug release from the carrier with the rate of prodrug elimination.
Assuntos
Liberação Controlada de Fármacos , Irinotecano/farmacocinética , Taxa de Depuração Metabólica , Pró-Fármacos/farmacocinética , Neoplasias de Mama Triplo Negativas/tratamento farmacológico , Animais , Antineoplásicos/farmacocinética , Portadores de Fármacos/farmacocinética , Sistemas de Liberação de Medicamentos , Meia-Vida , Substâncias Macromoleculares/farmacocinética , Camundongos , Polietilenoglicóis/farmacologia , Inibidores da Topoisomerase I/farmacocinética , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
Major objectives in nanomedicine and nanotherapy include the ability to trap therapeutic molecules inside of nano-carriers, carry therapeutics to the site of the disease with no leakage, release high local concentrations of drug, release only on demand - either autonomous or external, and kill the cancer cells or an infectious organism. This review will focus on mesoporous silica nanoparticle carriers (MSN) with a large internal pore volume suitable for carrying anticancer and antibiotic drugs, and supramolecular components that function as caps that can both trap and release the drugs on-command. Caps that are especially relevant to this review are rotaxanes and pseudorotaxanes that consist of a long chain-like molecule threaded through a cyclic molecule. Under certain conditions discussed throughout this review, the cyclic molecule can be attracted to one end of the rotaxane and in the presence of a stimulus can slide to the other end. When the thread is attached near the pore opening on MSNs, the sliding cyclic molecule can block the pore when it is near the particle or open it when it slides away. The design, synthesis and operation of supramolecular systems that act as stimuli-responsive pore capping devices that trap and release molecules for therapeutic or imaging applications are discussed. Uncapping can either be irreversible because the cap comes off, or reversible when the cyclic molecule is prevented from sliding off by a steric barrier. In the latter case the amount of cargo released (the dose) can be controlled. These nanomachines act as valves. Examples of supramolecular systems stimulated by chemical signals (pH, redox, enzymes, antibodies) or by external physical signals (light, heat, magnetism, ultrasound) are presented. Many of the systems have been studied in vitro proving that they are taken up by cancer cells and release drugs and kill the cells when stimulated. Some have been studied in mouse models; after IV injection they shrink tumors or kill intracellular pathogens after stimulation. Supramolecular constructs offer fascinating, highly controllable and biologically compatible platforms for drug delivery.
Assuntos
Antibacterianos/administração & dosagem , Antineoplásicos/administração & dosagem , Compostos de Cálcio , Sistemas de Liberação de Medicamentos , Substâncias Macromoleculares/administração & dosagem , Nanopartículas , Silicatos , Animais , Linhagem Celular , Humanos , Substâncias Macromoleculares/farmacocinética , Substâncias Macromoleculares/farmacologia , Camundongos , Nanomedicina/métodos , Nanomedicina/tendências , Rotaxanos/administração & dosagem , Rotaxanos/farmacocinética , Rotaxanos/farmacologiaRESUMO
Current treatments for intestinal diseases including inflammatory bowel diseases, irritable bowel syndrome, and colonic bacterial infections are typically small molecule oral dosage forms designed for systemic delivery. The intestinal permeability hurdle to achieve systemic delivery from oral formulations of macromolecules is challenging, but this drawback can be advantageous if an intestinal region is associated with the disease. There are some promising formulation approaches to release peptides, proteins, antibodies, antisense oligonucleotides, RNA, and probiotics in the colon to enable local delivery and efficacy. We briefly review colonic physiology in relation to the main colon-associated diseases (inflammatory bowel disease, irritable bowel syndrome, infection, and colorectal cancer), along with the impact of colon physiology on dosage form design of macromolecules. We then assess formulation strategies designed to achieve colonic delivery of small molecules and concluded that they can also be applied some extent to macromolecules. We describe examples of formulation strategies in preclinical research aimed at colonic delivery of macromolecules to achieve high local concentration in the lumen, epithelial-, or sub-epithelial tissue, depending on the target, but with the benefit of reduced systemic exposure and toxicity. Finally, the industrial challenges in developing macromolecule formulations for colon-associated diseases are presented, along with a framework for selecting appropriate delivery technologies.
Assuntos
Colo/metabolismo , Doenças do Colo/tratamento farmacológico , Sistemas de Liberação de Medicamentos , Substâncias Macromoleculares/administração & dosagem , Substâncias Macromoleculares/farmacocinética , Humanos , Substâncias Macromoleculares/uso terapêuticoRESUMO
The aim of this article is to collate the recent developments in the field of drug delivery, medical therapeutics and diagnostics specifically involving the nonlamellar liquid crystalline (NLC) systems. This review highlights different NLC phases having cubic, hexagonal and sponge internal structures, and their application in the field of drug delivery, such as dose reduction, toxicity reduction and therapeutic efficacy enhancement either in the form of nanoparticles, colloidal dispersion or gels. In addition, application of NLC systems as vehicles for peptides, proteins and as a theranostic system in cancer and other disease conditions is also elaborated, which is a growing platform of interest. Overall, the present review gives us a complete outlook on applications of NLC systems in the field of medicine.
Assuntos
Produtos Biológicos/administração & dosagem , Portadores de Fármacos/química , Cristais Líquidos/química , Substâncias Macromoleculares/administração & dosagem , Nanopartículas/química , Produtos Biológicos/farmacocinética , Química Farmacêutica , Humanos , Substâncias Macromoleculares/farmacocinética , Peptídeos/administração & dosagem , Peptídeos/farmacocinética , Nanomedicina Teranóstica/métodosRESUMO
Because of the unparalleled efficiency and universal utility in treating a variety of disease types, siRNA agents have evolved as the future drug-of-choice. Yet, the inability of the polyanionic siRNA macromolecules to cross the cell membrane remains as the bottleneck of possible clinical applications. With the cell penetrating peptides (CPP) being discovered lately, the most effective tactic to achieve the highest intracellular siRNA delivery deems to be by covalently conjugating the drug to a CPP; for instance, the arginine-rich Tat or low molecular weight protamine (LMWP) peptides. However, construction of such a chemical conjugate has been referred by scientists in this field as the "Holy Grail" challenge due to self-assembly of the cationic CPP and anionic siRNA into insoluble aggregates that are deprived of the biological functions of both compounds. Based on the dynamic motion of PEG, we present herein a concise coupling strategy that is capable of permitting a high-yield synthesis of the cell-permeable, cytosol-dissociable LMWP-siRNA covalent conjugates. Cell culture assessment demonstrates that this chemical conjugate yields by far the most effective intracellular siRNA delivery and its corresponded gene-silencing activities. This work may offer a breakthrough advance towards realizing the clinical potential of all siRNA therapeutics and, presumably, most anionic macromolecular drugs such as anti-sense oligonucleotides, gene compounds, DNA vectors and proteins where conjugation with the CPP encounters with problems of aggregation and precipitation. To this end, the impact of this coupling technique is significant, far-reaching and wide-spread.
Assuntos
Peptídeos Penetradores de Células/farmacocinética , Substâncias Macromoleculares/síntese química , Protaminas/farmacocinética , RNA Interferente Pequeno/farmacocinética , Tecnologia Farmacêutica/métodos , Linhagem Celular Tumoral , Humanos , Substâncias Macromoleculares/farmacocinéticaRESUMO
Poly(ß-L-malic acid) (PMLA), a natural aliphatic polyester, has been proven to be a promising carrier for anti-cancer drugs. In spite of excellent bio-compatibility, the application of PMLA as the drug carrier for cancer therapy is limited by its low cellular uptake efficiency. The strong negative charge of PMLA impedes its uptake by cancer cells because of the electrostatic repulsion. In this study, a dual pH-sensitive charge-reversal PMLA-based nanocomplex (PMLA-PEI-DOX-TAT@PEG-DMMA) was developed for effective tumor-targeted drug delivery, enhanced cellular uptake, and intracellular drug release. The prepared nanocomplex showed a negative surface charge at the physiological pH, which could protect the nanocomplex from the attack of plasma proteins and recognition by the reticuloendothelial system, so as to prolong its circulation time. While at the tumor extracellular pH 6.8, the DMMA was hydrolyzed, leading to the charge reversal and exposure of the TAT on the polymeric micelles, thus enhancing the cellular internalization. Then, the polymeric micelles underwent dissociation and drug release in response to the acidic pH in the lyso/endosomal compartments of the tumor cell. Both in vitro and in vivo efficacy studies indicated that the nanocomplex significantly inhibited the tumor growth while the treatment showed negligible systemic toxicity, suggesting that the developed dual pH-sensitive PMLA-based nanocomplex would be a promising drug delivery system for tumor-targeted drug delivery with enhanced anticancer activity.
Assuntos
Adenocarcinoma/tratamento farmacológico , Antineoplásicos/uso terapêutico , Portadores de Fármacos/farmacocinética , Substâncias Macromoleculares/farmacocinética , Malatos/farmacocinética , Terapia de Alvo Molecular/métodos , Polímeros/farmacocinética , Animais , Linhagem Celular Tumoral , Fenômenos Químicos , Modelos Animais de Doenças , Portadores de Fármacos/administração & dosagem , Endocitose , Xenoenxertos , Humanos , Concentração de Íons de Hidrogênio , Substâncias Macromoleculares/administração & dosagem , Malatos/administração & dosagem , Camundongos , Nanoestruturas/administração & dosagem , Polímeros/administração & dosagem , Resultado do TratamentoRESUMO
A mitochondria-targeting supramolecular photosensitizer system TPP-QAS/WP5/DTAB was constructed based on a host-guest inclusion complex. The supramolecular system could efficiently release and activate TPP-QASs in an acidic environment, which have been demonstrated to preferentially accumulate in mitochondria. Singlet oxygen (1O2) could be in situ generated in mitochondria under light irradiation, further enhancing the PDT efficacy.
Assuntos
Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Fotoquimioterapia , Fármacos Fotossensibilizantes/química , Fármacos Fotossensibilizantes/metabolismo , Compostos de Amônio Quaternário/metabolismo , Calixarenos , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Humanos , Substâncias Macromoleculares/química , Substâncias Macromoleculares/metabolismo , Substâncias Macromoleculares/farmacocinética , Substâncias Macromoleculares/farmacologia , Microscopia Confocal , Estrutura Molecular , Fármacos Fotossensibilizantes/farmacocinética , Fármacos Fotossensibilizantes/farmacologia , Compostos de Amônio Quaternário/química , Compostos de Amônio Quaternário/farmacocinética , Compostos de Amônio Quaternário/farmacologia , Relação Estrutura-AtividadeRESUMO
Since the first attempt to administer insulin orally in humans more than 90years ago, the oral delivery of macromolecular drugs (>1000g/mol) has been rather disappointing. Although several clinical pilot studies have demonstrated that the oral absorption of macromolecules is possible, the bioavailability remains generally low and variable. This article reviews the formulations and biopharmaceutical aspects of orally administered biomacromolecules on the market and in clinical development for local and systemic delivery. The most successful approaches for systemic delivery often involve a combination of enteric coating, protease inhibitors and permeation enhancers in relatively high amounts. However, some of these excipients have induced local or systemic adverse reactions in preclinical and clinical studies, and long-term studies are often missing. Therefore, strategies aimed at increasing the oral absorption of macromolecular drugs should carefully take into account the benefit-risk ratio. In the absence of specific uptake pathways, small and potent peptides that are resistant to degradation and that present a large therapeutic window certainly represent the best candidates for systemic absorption. While we acknowledge the need for systemically delivering biomacromolecules, it is our opinion that the oral delivery to local gastrointestinal targets is currently more promising because of their accessibility and the lacking requirement for intestinal permeability enhancement.
Assuntos
Substâncias Macromoleculares/administração & dosagem , Substâncias Macromoleculares/farmacocinética , Preparações Farmacêuticas/administração & dosagem , Administração Oral , Animais , Disponibilidade Biológica , Excipientes/efeitos adversos , Humanos , Insulina/administração & dosagem , Insulina/farmacocinética , Absorção Intestinal , Peptídeos/administração & dosagem , Peptídeos/farmacocinética , Medição de RiscoRESUMO
Macromolecular delivery strategies typically utilize the endocytic pathway as a route of cellular entry. However, endosomal entrapment severely limits the efficiency with which macromolecules penetrate the cytosolic space of cells. Recently, we have circumvented this problem by identifying the reagent dfTAT, a disulfide bond dimer of the peptide TAT labeled with the fluorophore tetramethylrhodamine. We have generated a fluorescently labeled dimer of the prototypical cell-penetrating peptide (CPP) TAT, dfTAT, which penetrates live cells and reaches the cytosolic space of cells with a particularly high efficiency. Cytosolic delivery of dfTAT is achieved in multiple cell lines, including primary cells. Moreover, delivery does not noticeably impact cell viability, proliferation or gene expression. dfTAT can deliver small molecules, peptides, antibodies, biologically active enzymes and a transcription factor. In this report, we describe the protocols involved in dfTAT synthesis and cellular delivery. The manuscript describes how to control the amount of protein delivered to the cytosolic space of cells by varying the amount of protein administered extracellularly. Finally, the current limitations of this new technology and steps involved in validating delivery are discussed. The described protocols should be extremely useful for cell-based assays as well as for the ex vivo manipulation and reprogramming of cells.
Assuntos
Peptídeos Penetradores de Células/administração & dosagem , Sistemas de Liberação de Medicamentos/métodos , Peptídeos/administração & dosagem , Proteínas/administração & dosagem , Linhagem Celular , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Peptídeos Penetradores de Células/química , Peptídeos Penetradores de Células/farmacocinética , Endocitose , Endossomos/metabolismo , Corantes Fluorescentes/administração & dosagem , Corantes Fluorescentes/química , Corantes Fluorescentes/farmacocinética , Células HeLa , Humanos , Substâncias Macromoleculares/administração & dosagem , Substâncias Macromoleculares/química , Substâncias Macromoleculares/farmacocinética , Peptídeos/farmacocinética , Polímeros/química , Proteínas/farmacocinética , Rodaminas/administração & dosagem , Rodaminas/química , Rodaminas/farmacocinéticaRESUMO
Pulmonary delivery is a non-invasive form of delivery that holds tremendous therapeutic promise for topical and systemic administration of several macromolecules. Oral administration of macromolecules has several limitations such as low bioavailability, degradation of drug before reaching circulation and insufficient absorption across intestinal membrane. Administration of macromolecules such as proteins, peptides and nucleic acids via inhalation offers great potential due to the avoidance of first pass metabolism, higher surface area and rapid clinical response. However, delivery of reproducible, uniform and safe doses of inhaled particles remains a major challenge for clinical translation. Recent advances in the fields of biotechnology and particle engineering led to progress in novel pulmonary drug delivery systems. Moreover, significant developments in carriers and delivery devices prevent denaturation of macromolecules and control their release within the lungs. This article reviews the advances in pulmonary drug delivery systems by focusing on the recent patents in delivery of macromolecules. Furthermore, recent patents in gene delivery to the lungs have also been discussed. List of patents included in this review is comprehensive in terms of pulmonary delivery of therapeutics. It includes inventions related to proteins and peptides, DNA therapeutics, siRNA and other genetic materials with therapeutic applications. The diseases targeted by these therapeutic molecules are varied including but not limited to different forms of cancer, respiratory diseases etc.
Assuntos
Portadores de Fármacos , Sistemas de Liberação de Medicamentos/métodos , Substâncias Macromoleculares/administração & dosagem , Patentes como Assunto , Tecnologia Farmacêutica/métodos , Administração por Inalação , Animais , Difusão de Inovações , Sistemas de Liberação de Medicamentos/tendências , Humanos , Pulmão/metabolismo , Substâncias Macromoleculares/química , Substâncias Macromoleculares/farmacocinética , Absorção pelo Trato Respiratório , Tecnologia Farmacêutica/tendênciasRESUMO
Small interfering RNA (siRNA) targeted therapeutics (STT) offers a compelling alternative to tradition medications for treatment of genetic diseases by providing a means to silence the expression of specific aberrant proteins, through interference at the expression level. The perceived advantage of siRNA therapy is its ability to target, through synthetic antisense oligonucleotides, any part of the genome. Although STT provides a high level of specificity, it is also hindered by poor intracellular uptake, limited blood stability, high degradability and non-specific immune stimulation. Since serum proteins has been considered as useful vehicles for targeting tumors, in this study we investigated the effect of incorporation of human serum albumin (HSA) in branched polyethylenimine (bPEI)-siRNA polyplexes in their internalization in epithelial and endothelial cells. We observed that introduction of HSA preserves the capacity of bPEI to complex with siRNA and protect it against extracellular endonucleases, while affording significantly improved internalization and silencing efficiency, compared to bPEI-siRNA polyplexes in endothelial and metastatic breast cancer epithelial cells. Furthermore, the uptake of the HSA-bPEI-siRNA ternary polyplexes occurred primarily through a caveolae-mediated endocytosis, thus providing evidence for a clear role for HSA in polyplex internalization. These results provide further impetus to explore the role of serum proteins in delivery of siRNA.
Assuntos
Sistemas de Liberação de Medicamentos/métodos , Células Endoteliais/metabolismo , Inativação Gênica/fisiologia , Substâncias Macromoleculares/metabolismo , RNA Interferente Pequeno/metabolismo , RNA Interferente Pequeno/uso terapêutico , Albumina Sérica/metabolismo , Cavéolas , Linhagem Celular Tumoral , Ensaio de Desvio de Mobilidade Eletroforética , Citometria de Fluxo , Inativação Gênica/efeitos dos fármacos , Humanos , Substâncias Macromoleculares/farmacocinética , Polietilenoimina/metabolismo , RNA Interferente Pequeno/genéticaRESUMO
The enhanced permeability and retention (EPR) effect of solid tumors as seen with nanomedicines and macromolecular drugs is well known. However, many researchers appear to lack a full understanding of this effect. The effect varies depending on a patient's pathological and physiological characteristics and clinical condition. When a patient's systolic blood pressure is low side of about 90mmHg instead of 120-130mmHg, the hydrodynamic force pushing blood from the luminal side of a vessel into tumor tissue becomes significantly low, which results in a low EPR. Also, a vascular embolism in a tumor may impede blood flow and the EPR. Here, I describe the background of the EPR effect, heterogeneity of this effect, physiological and pathological factors affecting the effect, the EPR effect in metastatic tumors, artifacts of the EPR effect with micellar and liposomal drugs, problems of macromolecular drug stability and drug release, and access to target sites.
Assuntos
Antineoplásicos/administração & dosagem , Sistemas de Liberação de Medicamentos , Neoplasias/tratamento farmacológico , Animais , Antineoplásicos/farmacocinética , Liberação Controlada de Fármacos , Humanos , Lipossomos , Substâncias Macromoleculares/administração & dosagem , Substâncias Macromoleculares/farmacocinética , Micelas , Nanomedicina , Neoplasias/patologia , PermeabilidadeRESUMO
INTRODUCTION: Various macromolecules including polypeptides, proteins, genes and polysaccharides have been drawing attention for their therapeutic potential. The passage through intestinal epithelium is the major barrier for the oral delivery of macromolecules, by either paracellular or transcellular pathways. However, most macromolecules are poorly absorbed in oral route due to their high molecular weight and low stability in the gastrointestinal (GI) tract. Nonetheless, advancing in oral macromolecular drug delivery will be significant in expanding the clinical use of therapeutic macromolecules. AREAS COVERED: Technologies using chemical conjugation, absorption enhancers and nano-/micro-particulate systems have been developed to improve oral bioavailability of macromolecules, and some of them are in the process of clinical trials. In this review, they are discussed in the context of their progression states, hurdles and modes of action. EXPERT OPINION: According to the better understanding of receptor or transporter structure and transport mechanisms in the GI tract, the progress ineffective oral delivery systems for therapeutic macromolecules is anticipated over the next decades. In addition, the advent of numerous particulate systems will also speed up the development of novel drug delivery technologies. This offers an optimistic perspective on the potential clinical usage of oral macromolecular drugs.
Assuntos
Substâncias Macromoleculares/uso terapêutico , Administração Oral , Animais , Disponibilidade Biológica , Humanos , Absorção Intestinal , Substâncias Macromoleculares/farmacocinéticaRESUMO
This study involves the development and functional characterization of a thiolated chitosan (CS) system for potential buccal delivery of proteins. Thiolated CS was synthesized by conjugating pure CS with thioglycolic acid and dialyzed to remove excess acid. Amount of thiol groups immobilized on CS was determined using L-cysteine calibration curve. The weight average molecular weights of CS and thiolated CS were monitored using gel permeation chromatography. Laminated wafers were obtained by pouring gels (containing bovine serum albumin; BSA, different amounts of glutathione as enzyme inhibitor and mucin to mimic salivary conditions) of the thiolated CS into moulds previously lined with impervious ethylcellulose (EC) films and freeze-dried. The resulting formulations were analyzed using attenuated total reflectance Fourier transform infrared (FTIR) spectroscopy, circular dichroism (CD) and scanning electron microscopy (SEM). The formulations were further characterized for functional buccal mucosa performance using hydration, swelling, mucoadhesion and in vitro drug dissolution studies. FTIR showed successful thiolation of CS's amine functionality, CD confirmed that BSA conformation remained unchanged throughout the gel formulation and freeze-drying process, whilst SEM showed a porous microstructure of the wafers and a uniform EC film laminate with no visible pores or cracks. The functional characterization studies showed that glutathione had significant effects on hydration, mucoadhesion and subsequently drug dissolution and release characteristics, whilst mucin affected the mucoadhesive properties of the wafers. It was concluded that BSA-loaded wafers containing 10% w/w glutathione as enzyme inhibitor was the formulation choice for potential buccal delivery and should be selected for further investigations.
Assuntos
Administração Bucal , Quitosana/análogos & derivados , Substâncias Macromoleculares/administração & dosagem , Animais , Bovinos , Química Farmacêutica , Quitosana/química , Formas de Dosagem , Sistemas de Liberação de Medicamentos , Estabilidade de Medicamentos , Liofilização , Géis , Glutationa , Substâncias Macromoleculares/farmacocinética , Microscopia Eletrônica de Varredura , Absorção pela Mucosa Oral , Soroalbumina Bovina/administração & dosagem , Soroalbumina Bovina/farmacocinética , Espectroscopia de Infravermelho com Transformada de Fourier , Comprimidos , TioglicolatosRESUMO
The potential pharmacokinetic interactions between macromolecules and small-molecule drugs have received more and more attention with the increasing development of macromolecule therapeutics. Studies have shown that cytokines can differentially modulate drug-metabolizing enzymes and transporters, which raises concerns on the potential interactions of therapeutic cytokines and cytokine modulators on the disposition of small-molecule drugs. Although many in vitro studies have been conducted to characterize the effects of cytokines on drug-metabolizing enzymes and transporters, these studies were limited to only a handful of cytokines, such as interleukin-1 (IL-1), IL-6, tumor necrosis factor-α, and interferon. It is also challenging to translate these in vitro results to in vivo. In addition, information on the impact of cytokine modulators on drug-metabolizing enzymes and transporters is rather limited. More research is needed in this area. The present review is to provide a summary of the in vitro findings on the pharmacokinetic interactions of therapeutic cytokines and cytokine modulators on small-molecule drugs. Discussion on current challenges in assessing these interactions is also included.
Assuntos
Citocinas/farmacocinética , Interações Medicamentosas/fisiologia , Animais , Sistema Enzimático do Citocromo P-450/efeitos dos fármacos , Sistema Enzimático do Citocromo P-450/fisiologia , Modelos Animais de Doenças , Glutationa Transferase/fisiologia , Humanos , Células de Kupffer/fisiologia , Substâncias Macromoleculares/farmacocinética , Proteínas de Membrana Transportadoras/fisiologiaRESUMO
Oral chemotherapy is an important topic in the 21st century medicine, which may radically change the current regimen of chemotherapy and greatly improve the quality of life of the patients. Unfortunately, most anticancer drugs, especially those of high therapeutic efficacy such as paclitaxel and docetaxel, are not orally bioavailable due to the gastrointestinal (GI) drug barrier. The molecular basis of the GI barrier has been found mainly due to the multidrug efflux proteins, i.e. P-type glycoproteins (P-gp), which are rich in the epithelial cell membranes in the GI tract. Medical solution for oral chemotherapy is to apply P-gp inhibitors such as cyclosporine A, which, however, suppress the body's immune system either, thus causing medical complication. Pharmaceutical nanotechnology, which is to apply and further develop nanotechnology to solve the problems in drug delivery, may provide a better solution and thus change the way we make drug and the way we take drug. This review is focused on the problems encountered in oral chemotherapy and the pharmaceutical nanotechnology solutions such as prodrugs, nanoemulsions, dendrimers, micelles, liposomes, solid lipid nanoparticles and nanoparticles of biodegradable polymers. Proof-of-concept in vitro and in vivo results for oral delivery of anticancer drugs by the various nanocarriers, which can be found so far from the literature, are provided.
Assuntos
Antineoplásicos/administração & dosagem , Antineoplásicos/farmacocinética , Portadores de Fármacos/administração & dosagem , Nanotecnologia/métodos , Adjuvantes Farmacêuticos/química , Adjuvantes Farmacêuticos/farmacocinética , Administração Oral , Disponibilidade Biológica , Transporte Biológico/fisiologia , Química Farmacêutica , Portadores de Fármacos/farmacocinética , Trato Gastrointestinal/metabolismo , Humanos , Absorção Intestinal/fisiologia , Lipossomos/farmacocinética , Substâncias Macromoleculares/administração & dosagem , Substâncias Macromoleculares/farmacocinéticaRESUMO
Macromolecular therapeutics, in particular, many biologics, is the most advancing category of drugs over conventional chemical drugs. The potency and specificity of the biologics for curing certain disease made them to be a leading compound in the pharmaceutical industry. However, due to their intrinsic nature, including high molecular weight, hydrophilicity and instability, they are difficult to be administered via non-invasive route. This is a major quest especially in biologics, as they are frequently used clinically for chronic disorders, which requires long-term administration. Therefore, many efforts have been made to develop formulation for non-invasive administration, in attempt to improve patient compliance and convenience. In this review, strategies for non-invasive delivery, in particular, oral, pulmonary and nasal delivery, that are recently adopted for delivery of biologics are discussed. Insulin, calcitonin and heparin were mainly focused for the discussion as they could represent protein, polypeptide and polysaccharide drugs, respectively. Many recent attempts for non-invasive delivery of biologics are compared to provide an insight of developing successful delivery system.